Jake: " (While the FDA has apparently never formal
Post# of 154597
(Total Views: 512)
Posted On: 03/24/2025 8:54:15 AM
Jake: " (While the FDA has apparently never formally recognized decreases in circulating tumor cells as a qualifying surrogate endpoint for accelerated approval purposes, it has recognized the possibility that circulating blood DNA may qualify.) Ultimately, it turned out that 75% (21 of 28) of the LL patients experienced significant decreases in their circulating tumor cells."
From my vantage point which is that of a non-science trained individual your comment here raises some questions for me. I instinctively think a count of a patient's circulating tumor cells would be a definitive analysis of that patient's prognosis and condition. Yet, it appears, from your comment that the FDA does not share that belief. Is the notion of a high ctc count a new or proven or unproven scientific notion? Thanks for your help.
From my vantage point which is that of a non-science trained individual your comment here raises some questions for me. I instinctively think a count of a patient's circulating tumor cells would be a definitive analysis of that patient's prognosis and condition. Yet, it appears, from your comment that the FDA does not share that belief. Is the notion of a high ctc count a new or proven or unproven scientific notion? Thanks for your help.
(3)
(0)